Sanofi Ventures reinvested in the vaccine developer through a series B round that followed a $51m series A 18 months ago.
US-based vaccine developer Icosavax completed a $100m series B round yesterday that included pharmaceutical firm Sanofi’s strategic investment arm, Sanofi Ventures.
Investment manager RA Capital Management led the round, which was also backed by fellow new investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Open Philanthropy and Surveyor Capital.
Qiming Venture Partners USA, Adams Street Partners and ND Capital (formerly known as NanoDimension) filled out the round, having joined Sanofi Ventures in the company’s…
